Hepatocellular Carcinoma Treatment Efficacy Data from Propensity Score Matching Study

253 patients with intermediate-advanced hepatocellular carcinoma were retrospectively analyzed to compare combination therapy with monotherapy. The study reports objective response rates, progression-free survival, and overall survival metrics for two treatment groups. Li-Wei Deng authored this research, which was last updated on April 10, 2026.

Use Cases

• Compare objective response rates (ORR) between combination and monotherapy groups based on reported percentages
• Analyze progression-free survival (PFS) trends based on median months and hazard ratios
• Evaluate overall survival (OS) outcomes based on median months and hazard ratios
• Associate treatment type with survival outcomes based on multivariate analysis results
• Compare safety profiles based on reported Grade 3/4 treatment-related adverse event rates

Strengths

• 253 patient records provide a basis for statistical analysis
• Propensity score matching was applied to reduce confounding bias
• Specific efficacy metrics are reported: ORR (63.1% vs. 40.0%), median PFS (13.3 vs. 7.1 months), median OS (20.1 vs. 14.6 months)
• Safety data includes Grade 3/4 TRAE rates (21.5% vs. 14.0%)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count for the matched subset (65 vs. 100) is known, but the full dataset structure is unknown
• The 72.6 KB file size suggests the dataset is likely a summary or manuscript, not raw patient-level data

Provenance

Source

figshare

Collection Method

Retrospective study of patient records

Freshness

Last updated 2026-04-10 06:02:34; freshness should be verified